Science, medicine, and the future: Assessing thrombotic risk
- 22 August 1998
- Vol. 317 (7157) , 520-523
- https://doi.org/10.1136/bmj.317.7157.520
Abstract
Editorial by Vandenbroucke Venous thrombosis and venous thromboembolism are major medical problems. Because the time and scope for intervention are limited, the key to reducing the high morbidity and mortality of these conditions is prevention. Increased understanding of thrombotic mechanisms together with the recent identification of subsets of patients who are at increased risk of thrombosis are enabling clinicians to predict risk more accurately and increase the scope for targeted prevention. This article discusses current approaches and future prospects for assessing thrombotic risk and their relation to prophylactic strategies and new treatments. In hospital practice, postmortem and other studies suggest that venous thromboembolism causes 10% of deaths and contributes to a further 15%. Although it is relatively less common in the community, where the prevalence varies with age between 1 in 10 000 and 1 in 1000 per year, it is still a major cause of concern. Anxiety runs highest when oral contraceptive or hormone replacement therapy is being considered, and a small number of women die each year from thrombosis associated with these agents. The importance of venous thrombosis is often considered largely in terms of risk of death, but this ignores considerable morbidity from the miserable and disabling postphlebitic syndrome, which will develop in >20% of survivors. In most cases thrombosis arises from a combination of external circumstances and the inherited and acquired predisposition to thrombosis of an individual. Only 30-40% of cases seem to be completely spontaneous. So far we have been better at identifying high risk circumstances than high risk individuals, and so the concept of screening people for risk of thrombosis is relatively new. The tendency of some individuals to develop thrombosis more easily than others is often inherited, and the term thrombophilia has been coined to describe this condition. We can now identify a …Keywords
This publication has 10 references indexed in Scilit:
- An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN).1997
- A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosisBlood, 1996
- Factor V Leiden: should we screen oral contraceptive users and pregnant women?BMJ, 1996
- Inherited Thrombophilia: Part 1Thrombosis and Haemostasis, 1996
- Factor V Leiden (FV R506Q) in Families with Inherited Antithrombin DeficiencyThrombosis and Haemostasis, 1996
- Inherited Thrombophilia*: Part 2Thrombosis and Haemostasis, 1996
- 6 Activation markers of coagulationBailliere's Clinical Haematology, 1994
- Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.1994
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.Proceedings of the National Academy of Sciences, 1993